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REVIEW
Abstract: Moxifloxacin is a recent addition to the fluoroquinolone class, differing from
ciprofloxacin and other older agents in having much better in vitro activity against Gram-
positive aerobes while retaining potent activity against Gram-negative aerobes. It is also
active against the pathogens of human and animal bite wounds and those species of atypical
mycobacteria associated with dermatologic infections. Its activity against anaerobes is quite
variable. Moxifloxacin penetrates well into inflammatory blister fluid and muscle and
subcutaneous adipose tissues. Moxifloxacin should thus be a reasonable option for the treatment
of skin and skin structure infections (SSSIs). In 3 randomized controlled trials (RCTs), oral
moxifloxacin was as effective as cephalexin in the treatment of uncomplicated SSSIs in adults
while in 2 RCTs, intravenous/oral moxifloxacin was as effective as intravenous/oral β-lactam/
β-lactamase inhibitor therapy in the treatment of complicated SSSIs in adults. Moxifloxacin
does not inhibit cytochrome P450 enzymes and thus interact with warfarin or methylxanthines.
However, multivalent cations can reduce its oral bioavailability substantially. Dosage
adjustment is not required in the presence of renal or hepatic impairment. The clinical relevance
of its electrophysiologic effects (QTc prolongation) remains unresolved.
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Introduction
Moxifloxacin is one of most-recently marketed of the fluoroquinolone (hereafter
called quinolone) antimicrobials (Avelox
®, Bayer, Leverkusen, Germany). Of this
group (gatifloxacin, gemifloxacin, moxifloxacin), only moxifloxacin has regulatory
approval for use in skin and skin structure infections (SSSIs) (Anonymous 2005).
Until recently, this approval was limited to uncomplicated SSSIs in adults caused by
Staphylococcus aureus or Streptococcus pyogenes (Anonymous 2005). In June of
2005, it also received approval for use in complicated SSSIs caused by methicillin-
susceptible S. aureus, Escherichia coli, Klebsiella pneumoniae, and Enterobacter
cloacae (Anonymous 2005). Complicated SSSIs are defined as those which involve
deeper layers such as fascia or muscle, require significant surgical interventions, or
arise in the presence of significant comorbidities such as diabetes or HIV infection
(Raghavan and Linden 2004). The purpose of this paper is to review the in vitro
antimicrobial activity, pharmacokinetics, clinical and bacteriological efficacy, safety,
tolerability, and drug–drug interaction potential of moxifloxacin, concentrating on
its potential role in the treatment of complicated (and uncomplicated) SSSIs.
Mechanisms of action and resistance
Moxifloxacin acts by the same mechanism as other quinolones: inhibition of bacterial
DNA gyrase (a Type II topoisomerase composed of two gyr A and two gyr B subunits)
and topoisomerase IV (a heterotetramer made up of two par C and two par E subunits
(Ruiz 2003; Mitscher 2005). Topoisomerase IV is felt to be the preferred target,
especially in Gram-positive aerobes (Ince et al 2003). Resistance is mediated in all
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quinolones by either changes in the target site (DNA gyrase
and/or topoisomerase IV) or changes that alter intracellular
drug accumulation (ie, enhanced efflux).
In vitro antimicrobial activity
Unlike earlier quinolones like ciprofloxacin, moxifloxacin
has significant activity against Gram-positive aerobes,
including potential dermatologic pathogens such as S.
aureus, coagulase-negative staphylococci, and groups A/
B/C/F/G streptococci (Table 1) (Dalhoff et al 1996;
Bauernfeind 1997; Fass 1997; Goldstein et al 1997, 2000;
Woodcock et al 1997; Barry et al 1999; Malathum et al 1999;
von Eiff et al 1999; Blondeau et al 2000; Fung-Tomc et al
2000; Hardy et al 2000; Hoogkamp-Korstanje et al 2000;
Milatovic et al 2000; Amabile-Cuevas et al 2001; Blondeau
2002; Speciale et al 2002; Bowker et al 2003; Hsueh et al
2003; Noviello et al 2003; Edmiston et al 2004, 2005; Jacobs
et al 2004; Patel et al 2004; Wenzler et al 2004; Bogdanovich
et al 2005; Stratchounski et al 2005). Methicillin-resistant
strains of staphylococci are much less susceptible and
enterococci are only moderately susceptible to moxifloxacin.
Moxifloxacin still retains significant activity against Gram-
negative aerobes with the exception of variable activity
against Pseudomonas aeruginosa, other pseudomonads, and
Stenotrophomonas maltophilia (Table 1). Among anaerobes,
moxifloxacin is quite active against the majority of
pathogens of animal and human bite wounds. Activity
against Bacteroides, Fusobacterium, and Prevotella species
is variable (Table 2) (Dalhoff et al 1996; Aldridge and
Ashcraft 1997; Bauernfeind 1997; Fass 1997; Goldstein et
al 1997; MacGowen et al 1997; Woodcock et al 1997;
Edlund et al 1998; Betriu et al 1999; Ackermann et al 2000;
Fung-Tomc et al 2000; Goldstein et al 2000, 2002, 2006;
Hoogkamp-Korstanje et al 2000; Milatovic et al 2000;
Schaumann et al 2000; Hoellman et al 2001; Snydman et al
2002; Speciale et al 2002; Ednie et al 2003; Hedberg et al
2003; Edmiston et al 2004, 2005; Peric et al 2004;
Sillerstrom et al 2004; Lion et al 2006).
Moxifloxacin has significant activity against many
strains of atypical mycobacteria, microorganisms of
significance in dermatological infections. For example, the
following minimum inhibitory concentrations of 90% of
isolates (MIC90) values (in mg/L) have been reported for a)
Mycobacterium marinum, b) M. fortuitum, c) M. chelonae,
d) M. abscessus, e) M. kansasii, and f) M. gordonae: a) 8.0
(43 isolates) (Braback et al 2002), 1.0 (53 isolates) (Aubry
et al 2000); b) 16.0 (69 isolates) (Yang et al 2003), 1.0 (7
Table 1 In vitro activity of moxifloxacin against potential Gram-positive and Gram-negative aerobic pathogens in SSSIs
Organism Isolates (n) Range of MIC90s (mg/L) References
Staphylococcus aureus 1427 0.03–>4.0 (1–6)
methicillin-sensitive 1221 0.06–4.0 (7–21, 27)
methicillin-resistant 1036 2–16 (2, 7–12, 14–21)
S. epidermidis 183 0.06–4.0 (3, 5, 18, 20)
methicillin-sensitive 424 0.06–2.0 (9–12, 15–17, 19, 22)
methicillin-resistant 641 0.12–>8.0 (9–12, 14–17, 19, 27)
Group A streptococci 1882 0.12–0.50 (2,6–9,11,13,15, 18–20, 23–25)
Group B streptococci 139 0.12–0.50 (6, 9, 11, 15, 18, 19, 23)
Enterococcus faecalis 438 0.25–16 (2, 6, 9, 11, 13–15, 18–23, 27)
E. faecium 263 2–≥32 (6, 9, 11, 13–15, 18, 20, 23, 27)
Escherichia coli 795 0.015–1.0 (2, 13–16, 18, 19, 22, 26, 27)
Klebsiella pneumoniae 619 0.031–1.0 (2, 14–16, 18, 19, 27)
Citrobacter freundii 290 1–4 (11, 14–16, 18, 19, 22, 27)
Morganella morganii 248 0.13–16 (11, 14–16, 18–20)
Proteus mirabilis 530 0.25–16 (2, 11, 14–16, 18–22, 27)
Enterobacter cloacae 541 0.06–2 (11, 14–16, 18, 19, 27)
E. aerogenes 325 0.5–>16 (11, 14–16, 18, 19, 27)
Pseudomonas aeruginosa 2376 4–64 (2, 11, 13, 15, 16, 18– 22, 27)
P. vulgarus 141 0.25–1 (11, 15, 16, 18, 20, 22)
Acinetobacter calcoaceticus 60 0.06–1 (2, 11, 22)
Abbreviations: MIC90, minimum inhibitory concentration for 90% of isolates.
Note: For entries with multiple studies, data are the range. To be included, studies had to have a minimum of 10 isolates of the microorganism-of-interest, use a
National Committee for Clinical Laboratory Standards - approved methodology, and an inoculum of 104–10
6 organisms.
References: 1, Stratchounski et al 2005; 2, Blondeau et al 2000; 3, Jacobs et al 2004; 4, Goldstein et al 2000; 5, Goldstein et al 1997; 6, Malathum et al 1999; 7,
Bowker et al 2003; 8, Noviello et al 2003; 9, Speciale et al 2002; 10, von Eiff et al 1999; 11, Bauernfeind 1997; 12, Patel et al 2004; 13, Wenzler et al 2004; 14, Edmiston
et al 2004; 15, Fung-Tomc et al 2000; 16, Milatovic et al 2000; 17, Hardy et al 2000; 18, Barry et al 1999; 19, Fass 1997; 20, Woodcock et al 1997; 21, Bogdanovich et al
2005; 22, Dalhoff et al 1996; 23, Hoogkamp-Korstanje et al 2000; 24, Hsueh et al 2003; 25, Amabile-Cuevas et al 2001; 26, Blondeau 2002; 27, Edmiston et al 2005.Therapeutics and Clinical Risk Management 2006:2(4) 419
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isolates) (Gillespie and Billington 1999), 0.5 (16 isolates)
(Rodriguez Diaz et al 2003); c) 8.0 (39 isolates) (Yang et al
2003), 16.0 (4 isolates) (Rodriguez Diaz et al 2003); d) 16.0
(92 isolates) (Yang et al 2003); e) 0.06 (16 isolates)
(Gillespie and Billington 1999), 0.06 (148 isolates) (Alcaide
et al 2004), 2.0 (8 isolates) (Rodriguez Diaz et al 2003); f)
0.5 (23 isolates) (Rodriguez Diaz et al 2003).
Important microorganisms in the context of skin and skin
structure infections related to foreign devices are the
coagulase-negative staphylococci (CNS), especially those
strains able to produce biofilm (an extracellular glycocalyx
material also called “slime”). Moxifloxacin’s activity has
been evaluated in vitro against 19 biofilm-producing (MIC90
= 2 mg/L) and 22 biofilm-nonproducing (MIC90 = 0.25 mg/
L) strains of CNS. SubMIC concentrations of moxifloxacin
did not modify biofilm production. It had poor activity
against stationary phase microorganisms but had some
activity against microorganisms in the biofilm. However,
high drug concentrations were necessary for this activity
(50- and 100-fold MIC concentrations produced mean 1.10
and 1.69 log reductions in bacterial counts, respectively)
(Perez-Giraldo et al 2004). In these regards, moxifloxacin
unfortunately behaved like many other antimicrobials
evaluated previously.
In another study with potential application to foreign
device-related infections, an in vitro study was performed
evaluating the bactericidal activity of moxifloxacin
monotherapy and combination moxifloxacin plus
vancomycin/teicoplanin therapy in 9 S. aureus isolates (1
being methicillin- and quinolone-sensitive and 8 being
resistant to both). These isolates came from patients
unresponsive to glycopeptide therapy or relapsing after
completion of glycopeptide therapy despite device removal.
Moxifloxacin MICs were 0.125 mg/L (in the 1 methicillin-
sensitive isolate) and 2.0 mg/L (in all of the methicillin-
resistant isolates). All isolates were tolerant to vancomycin,
teicoplanin, and moxifloxacin at medium concentrations 2
X MIC. However, moxifloxacin plus glycopeptide
combination therapy was bactericidal at the glycopeptide
MIC and 0.5 X MIC of moxifloxacin (Tarasi et al 2003).
Thus, combination therapy may be worthwhile considering
in difficult-to-treat patients.
Characteristic of quinolones, moxifloxacin has
concentration-dependent bactericidal activity (Dalhoff et al
1996). This has been shown with methicillin-sensitive and
-resistant S. aureus and coagulase-negative staphylococci
(Lister 2001, Speciale et al 2002; Noviello et al 2003;
Bogdanovich et al 2005), S. pyogenes (Esposito et al 2000;
Table 2 In vitro activity of moxifloxacin against potential bite wound pathogens and Gram-positive and Gram-negative anaerobic
pathogens in SSSIs
Organism Isolates (n) Range of MIC90s (mg/L) References
Pasturella canis 53 0.015–0.063 (1, 12, 25)
P. multocida subsp. multocida 217 0.015–0.06 (1, 2, 12, 25)
P. multocida subsp. septicum 104 0.016–0.03 (1, 2, 12, 25)
P. stomatis 48 ≤0.015–0.125 (1, 12, 25)
Ef-4b 38 0.06–0.25 (1, 2)
Eikenella corrodens 40 0.06–0.125 (1, 2)
Peptostreptococci 376 0.25–2 (1, 6, 7, 9, 13–18)
Clostridium perfringens 312 0.25–4 (5–9, 13–18, 26, 27)
C. difficile 344 1–4 (4, 6, 7, 9, 11, 13–17)
Bacteroides fragilis 2132 0.25–8 (3–6, 8–10, 13–24, 26, 27)
B. vulgatus 357 1–≥32 (5, 14–16, 18–22, 24, 26, 27)
B. ovatus 407 2–32 (5, 15, 16, 18–22, 24, 26, 27)
B. thetaiotaomicron 735 1–32 (5, 6, 8, 14–16, 18–24, 26, 27)
B. distasonis 199 0.5–8 (5, 14–16, 18, 24, 26, 27)
Fusobacterium sp. 307 0.12–>8 (1, 5, 6, 8, 14–19, 22, 26, 27)
F. nucleatum 129 0.125–>8 (1, 2, 5, 13–16, 26, 27)
Prevotella sp. 130 0.5–4 (1, 5, 7, 19, 22, 26, 27)
Abbreviations: MIC90 = minimum inhibitory concentration for 90% of isolates.
Notes: For entries with multiple studies, data are the range. To be included, studies had to have a minimum of 10 isolates of the microorganism-of-interest, use a
National Committee for Clinical Laboratory Standards – approved methodology, and an inoculum of 10
4–10
6 organisms.
References: 1, Goldstein et al 2000; 2, Goldstein et al 1997; 3, Speciale et al 2002; 4, Bauernfeind 1997; 5, Edmiston et al 2004; 6, Fung-Tomc et al 2000; 7, Milatovic
et al 2000; 8, Fass 1997; 9, Woodcock et al 1997; 10, Dalhoff et al 1996; 11, Hoogkamp-Korstanje et al 2000; 12, Goldstein et al 2002; 13, Sillerstrom et al 2004; 14,
Peric et al 2004; 15, Ednie et al 2003; 16, Hoellman et al 2001; 17, Edlund et al 1998; 18, Aldridge and Ashcraft 1997; 19, Schaumann et al 2000; 20, MacGowan et al
1997; 21, Snydman et al 2002; 22, Ackermann et al 2000; 23, Betriu et al 1999, 24, Hedberg et al 2003; 25, Lion et al 2006; 26, Goldstein et al 2005; 27, Edmiston et al
2005.Therapeutics and Clinical Risk Management 2006:2(4) 420
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Odenholt et al 2002; Speciale et al 2002; Noviello et al
2003), Enterococcus faecalis (Speciale et al 2002), and a
variety of anaerobes (Credito et al 2003). Bactericidal
activity using serum bactericidal titer technology has been
demonstrated for S. aureus, S. epidermidis, S. pyogenes, E.
coli, and Klebsiella pneumoniae (Lemmen et al 2003; Dan
et al 2004). Also, bactericidal activity using synovial fluid
bactericidal titer technology has been demonstrated for S.
aureus, S. pyogenes, and K. pneumoniae (Dan et al 2004).
Activity against S. pyogenes is independent of the presence/
absence of macrolide resistance determinants (Critchley et
al 2002).
Two recent studies have evaluated the activity of
moxifloxacin in in vitro pharmacokinetic/pharmacodynamic
models (IVP/PM) of mixed aerobic-anaerobic infection.
Hermsen and colleagues (2005) demonstrated bactericidal
activity against Escherichia coli and Bacteroides fragilis in
a study using a limited number of isolates of both
microorganisms. Using different strains of the same
microorganisms, Schaumann and colleagues (2005)
demonstrated that the presence of B. fragilis did not affect
the activity of moxifloxacin against E. coli but the presence
of E. coli reduced the activity against B. fragilis significantly.
Another recent study evaluated the pharmacodynamics
of moxifloxacin against anaerobes in an IVP/PM. B. fragilis,
Clostridium perfringens, and Gram-positive anaerobic cocci
(GPAC) were studied. Dose-ranging using area under the
concentration-time curve/minimum inhibitory concentration
(AUC/MIC) ratios of 6.7 to 890 (for the reference aerobe
E. coli) and 9 to 216 (for the anaerobes) revealed differing
AUC/MIC antibacterial effect patterns for anaerobes versus
the aerobe. For E. coli, the AUC/MIC ratios for 50%/90%
effect were 34/59 while the corresponding values for B.
fragilis, C. perfringens, and GPAC were 11/26, 9/16, and
7/17, respectively. At similar AUC/MIC ratio values, the
activity against anaerobes was less than that against the
aerobe. Using Monte Carlo simulations of human
pharmacokinetic data and a target anaerobic AUC/MIC ratio
value of 7.5, over 90% achievement of this target was
possible at MICs < 2 mg/L. The clinical implications of this
“pharmacokinetic breakpoint” of 2 mg/L for anaerobes
deserves further study (Noel et al 2005).
Despite 10- to 20-fold accumulation of drug
intracellularly (vida infra), the bactericidal effect of
moxifloxacin intracellularly develops slowly, with only a
1.51 log reduction in post-phagocytosis S. aureus inoculum
within 24 h (Seral et al 2003). This may be explainable, in
part, by the deleterious effect of acid pH on activity. For
example, at pH 5 (mimicking phagolysosome pH),
moxifloxacin activity falls at least 4-fold compared with
physiologic pH (Seral et al 2003). However, over a pH range
of 6 to 8, moxifloxacin activity is unaffected for S. aureus
and S. pyogenes (Dalhoff et al 2005).
The presence of 10%, 30%, and 50% albumin and human
serum had no significant effect on the in vitro activity of
moxifloxacin (Woodcock et al 1997; Rubinstein et al 2000).
The presence of dead bacteria, sterile pus under aerobic
conditions, sterile pus under anaerobic conditions, and
anaerobic conditions alone had no significant effect on the
in vitro activity of moxifloxacin against methicillin-sensitive
and -resistant staphylococci, S. pyogenes, and E. coli
(Boswell et al 1997; Rubinstein et al 2000; Wright et al
2002; Noel et al 2005). Anaerobic conditions also do not
alter the AUC/MIC ratios for 50% and 90% of effect for E.
coli and moxifloxacin (Noel et al 2005). Mixed effects have
been noted when testing for an inoculum effect (Boswell et
al 1997; Woodcock et al 1997).
Moxifloxacin has been evaluated in two mouse models
relevant to skin and skin structure infections (systemic
infection induced by intraperitoneal inoculation and cellulitis
induced by subcutaneous (SC) inoculation). In the systemic
infection model using 2 strains of methicillin-sensitive S.
aureus (both having a moxifloxacin MIC of 0.06 mg/L), the
ED50 and ED90 values for SC dosed drug were 0.6 mg/kg,
1.0 mg/kg and 1.7 mg/kg, 2.3 mg/kg, respectively, while
corresponding ED values for orally dosed drug were 3.2 mg/
kg (for both) and 9.6 mg/kg (for both) (Patel et al 2004).
The term ED50/90 refers to the doses effective in producing
survival rates of 50% and 90%, respectively. In the mouse
cellulitis model, one methicillin-sensitive strain (MIC
0.03mg/L) and two methicillin-resistant strains (MICs 1 mg/
L and 4 mg/L) of S. aureus were used. For the methicillin-
sensitive strain, 2.5 mg/kg and 5 mg/kg SC doses of
moxifloxacin were administered 1 h, 4 h, 24 h, and 27 h post-
inoculation while for the methicillin-resistant strains, 25 mg/
kg and 50 mg/kg SC doses were administered 1 h, 3 h, and
5 h post-inoculation. With the methicillin-sensitive strain,
moxifloxacin proved to be bacteriostatic (even 5 mg/kg
doses led to a <2 log colony forming unit (CFU) reduction/
lesion). With one methicillin-resistant strain, there was a
marginal fall in CFU/lesion while with the other, it had no
effect (CFU increased) (Patel et al 2004).
Two recent studies have evaluated the activity of
moxifloxacin in animal models of osteomyelitis (bone
infection). Bone infection can occur as a result of
hematogenous seeding or contiguous spread from an areaTherapeutics and Clinical Risk Management 2006:2(4) 421
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of soft tissue infection. One study compared moxifloxacin
and vancomycin in the treatment of bone infections due to
methicillin-sensitive S. aureus in rats. Moxifloxacin (10 mg/
kg) and vancomycin (15 mg/kg) were both dosed twice daily
by the intraperitoneal route. Moxifloxacin was significantly
more effective in reducing bacterial colony counts in femoral
bone than were placebo and vancomycin (both p<0.001;
placebo vs vancomycin, p=0.53). However, no treatment
sterilized the infected bone, probably due to the presence
of foreign material (ie, the hollow needle maintained in the
cavity) (Kalteis et al 2006a). The second study extended
the findings of the first to include bacterial counts in infected
capsular soft tissue and biofilm adherent to the implanted
needle. Moxifloxacin was significantly superior to
vancomycin and placebo in reducing bacterial counts in
capsular soft tissue (both p<0.001; placebo vs vancomycin,
p=0.09) and biofilm (p=0.009 and p<0.001, respectively;
placebo vs vancomycin, p=0.20) (Kalteis et al 2006b).
Further investigation of moxifloxacin in osteomyelitis
appears warranted.
Another atypical mycobacterial infection with
dermatological manifestations is leprosy (due to M. leprae).
The classic test for evaluating the activity of antimicrobials
against this microorganism is the mouse footpad model
wherein the microorganism is injected into the footpad. In
this model, where all drugs were administered orally,
moxifloxacin proved superior to the quinolone used most
frequently to date in combination regimens for leprosy,
ofloxacin (percentages killed of 92.1% vs 60.2%,
respectively; p<0.05). In addition, the combination of
minocycline plus moxifloxacin was superior to that of
minocycline plus ofloxacin (percentages killed of 93.7%
vs 74.9%, respectively; p<0.05). Moxifloxacin was
equipotent with rifampin, one of the key anti-leprosy drugs
(percentage killed by both drugs was 92.1%, p=NS). The
most potent combination tested was rifapentine (a rifamycin)
plus minocycline plus moxifloxacin which produced a
99.9% killing rate (Ji and Grosset 2000). Moxifloxacin is
an important agent to evaluate in vivo in human leprosy.
Performing large-scale surveillance of antimicrobial
susceptibility can assist in deciding upon the selection of
empiric antimicrobial therapy. In one such study, performed
between 1994 and 2001, 12 US hospitals collected 4434
Bacteroides isolates for susceptibility testing. The overall
moxifloxacin resistance rate rose from 30% to 43%
(p<0.001) from 1998 to 2001 (2001 MIC90 = 16 mg/L).
Increased moxifloxacin resistance over time was noted in
all species, all infection sites, and in 11 of 12 hospitals. For
blood isolates, the resistance rate rose from 38% in 1998 to
52% in 2001. Resistance rates were especially high in the
species ovatus, uniformis, and vulgatus. The largest increase
in resistance occurred with the species distasonis (22% in
1999 to 37% in 2001). Of all infection sites, decubitus ulcer
isolates had the highest resistance rates. On multivariate
analysis, the association between the year of
microorganism isolation and increased resistance rates
remained significant after adjusting for hospital, species,
and infection site (adjusted odds ratio=1.33, p<0.001)
(Golan et al 2003).
In the LIBRA surveillance study in the US in 1999, 324
laboratories participated in an examination of resistance rates
in S. pyogenes isolates. Isolates came from the respiratory
tract (n=2039), skin and skin structure (n=405) and blood
(n=148). The modal moxifloxacin MIC was 0.12 mg/L and
the MIC90 was 0.25 mg/L. One hundred percent of isolates
were susceptible (based on a resistance breakpoint of ≥4 mg/
L) (Critchley et al 2002).
In 2003, 37 laboratories in 19 countries participated in a
survey of resistance rates among B. fragilis group isolates.
Among the 1284 isolates (the majority coming from
abdominal infections and wounds), 9% were resistant to
moxifloxacin (breakpoint = 8 mg/L) (range 0%–22%).
Moxifloxacin resistance was commonest in Mediterranean
Europe (15%) and the UK (22%). In the various infection
types, the rates of intermediate (decreased susceptibility)
plus resistant isolates were as follows: abdominal infections
(5%), wounds (13%), abscesses (4%), blood (11%), and
external ulcers/skin infections (16%) (Hedberg et al 2003).
In 2005, results of a six-year (1997-2002) surveillance
study of moxifloxacin susceptibility among B. fragilis group
organisms at a single hospital in Spain were published.
Resistance rates to moxifloxacin rose from 6% (1997) to
16.5% (2002), using an MIC breakpoint of 8 mg/L (p<0.005
for trend). Examining resistance rates by species, these rates
rose over six years from 1.5% to 12% (B. fragilis), 10.3%
to 25% (B. thetaiotaomicron), and 15.4% to 36.8% (B.
uniformis) (Betriu et al 2005).
Results of the SENTRY Antimicrobial Surveillance
Program (1997–2004) have revealed the emergence in North
America and Europe of quinolone resistance among β-
hemolytic streptococci (groups A, B, C, G). Although rates
are low at present (0.51% and 0.14% in North America and
Europe, respectively), further dissemination and expansion
of resistance determinants is likely (Biedenbach et al 2006).Therapeutics and Clinical Risk Management 2006:2(4) 422
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Pharmacokinetics
Moxifloxacin is well-absorbed after oral administration,
with absolute oral bioavailabilities of 92% (mean) (range
77%–120%) and 86.2 ± 1.11% (mean ± standard deviation
[SD]) being noted in 2 healthy-volunteer studies (Ballow et
al 1999; Stass and Kubitza 1999). Oral administration in
the fed state (high fat breakfast) had nonsignificant effects
on moxifloxacin peak plasma concentration (Cmax) and area
under the plasma concentration-versus-time curve (AUC)
but did prolong the median time to Cmax (Tmax) from 1 to 2.5
hours (not clinically significant) (Lettieri et al 2001). Milk
(240–300 mL) and yogurt (250–300 mL) coadministration
did not significantly alter moxifloxacin bioavailability (Guay
2005) nor did enteral feeding coadministration (Burkhardt
et al 2005). Minor accumulation occurs during multiple
dosing and its pharmacokinetics are linear and dose-
proportional (Stass et al 1998, 2001; Sullivan et al 1999).
Mean ± SD plasma protein binding values of
moxifloxacin were 48% ± 2.5% (Stass et al 1998) and 39.4%
± 2.4% (Stass and Kubitza 1999). Plasma protein binding
of the M1 sulfocompound metabolite was 89.5% ± 0.9%
and that of the M2 glucuronide metabolite was 4.8% ± 4.1%
(Stass and Kubitza 1999). Penetration of moxifloxacin into
body compartments relevant to skin and skin structure
infections has been the subject of several studies. In one
healthy volunteer study, the pharmacokinetics of
moxifloxacin in plasma and inflammatory blister fluid
(induced by cantharides plasters) were evaluated after single
400 mg oral and intravenous doses. The mean ± SD (range)
penetration of moxifloxacin into inflammatory blister fluid
after oral and intravenous dosing were 83.5% ± 14.9%
(61%–103%) and 93.7% ± 8.3% (81%–104%), respectively,
as measured by AUC0-∞ (Wise et al 1999). In another study,
the serum and synovial fluid concentrations of moxifloxacin
after the last of three once-daily oral moxifloxacin 400 mg
doses were assessed in 20 patients undergoing knee
arthroscopy (mean age of 71.2 years). At 2 h, 6 h, 12 h, and
24 h after the last dose, the mean ± SD serum/synovial fluid
concentrations were 2.42 ± 0.4/2.76 ± 0.24 mg/L, 3.46 ±
0.78/3.42 ± 0.51 mg/L, 1.74 ± 0.26/1.61 ± 0.5 mg/L, and
1.5 ± 0.21/1.23 ± 0.14 mg/L, respectively (Dan et al
2004).
In yet another healthy volunteer study, the penetration
of moxifloxacin into the interstitial fluid compartments of
muscle and SC adipose fat tissue and inflammatory blister
fluid were evaluated after single 400 mg oral and intravenous
doses. Mean ± SD penetration into muscle interstitial fluid
was 55% ± 12% (using AUCmuscle/AUCtotal plasma data) and
86% ± 17% (using AUCmuscle/AUCfree plasma data data).
Corresponding SC adipose fat interstitial fluid penetration
was 38% ± 9% and 81% ± 19%. These results suggest a
virtually total equilibration between these two body
compartments and free (unbound) drug in plasma. The
concentration over time profiles in these two compartments
were virtually superimposable. Mean ± SD penetration into
inflammatory blister fluid (BF) was 64% ± 21% (using
AUCBF/AUCtotal plasma data) (Muller et al 1999).
The penetration of moxifloxacin into healthy and
inflamed SC adipose fat tissues was assessed in 11 patients
with skin and skin structure infections (n=5 had diabetes
and peripheral occlusive arterial disease (POAD), n=6 did
not). A single 400 mg IV dose of moxifloxacin was
administered over one hour. In the aggregate analysis (n=11),
drug concentrations in healthy and inflamed tissues were
consistently below total plasma concentrations and
approximately equal to free plasma concentrations.
Moxifloxacin total plasma concentration over time profiles
were similar in patients with and without diabetes/POAD.
Penetration into tissue did not statistically differ in the two
groups. In patients with diabetes/POAD, the concentrations
in healthy tissue exceeded those in inflamed tissue. Only
the healthy tissue concentrations were similar to the free
concentrations in plasma (the inflamed tissue concentrations
were about 1/2 of the free concentrations in plasma). In the
patients without diabetes, exactly the opposite findings were
noted. Thus, the mean ± SD AUC0-8h for inflamed tissue/
AUC0-∞ for free drug in plasma was 0.5 ± 0.4 in patients
with diabetes/POAD and 1.2 ± 0.8 in the other group. Mean
± SD inflamed tissue Cmax values were 0.8 ± 0.5 mg/L in
patients with diabetes/POAD and 2.3 ± 1.2 mg/L in the other
group. The reduced concentrations in inflamed tissues in
patients with versus without diabetes/POAD was perhaps
due to the vascular compromise associated with POAD.
None of these differences between patients with/without
diabetes/POAD were significant due to small sample sizes
and large interpatient variability. In all cases, tissue and
plasma drug concentrations exceeded the MICs of most
dermatologic pathogens, suggesting a role for moxifloxacin
in the treatment of skin and skin structure infections
(Joukhadar et al 2003).
Thirty patients undergoing total knee arthroplasty
participated in a study investigating the penetration of
moxifloxacin into bone. Ten patients received oral
moxifloxacin 2 h (range 1.5–2.5 h) preoperatively and mean
plasma, cancellous bone, and cortical bone drug
concentrations were 3.45 mg/L, 1.89 mg/kg, and 1.43 mg/Therapeutics and Clinical Risk Management 2006:2(4) 423
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kg, respectively. In the ten patients receiving moxifloxacin
4 h (range 3.5–4.5 h) preoperatively, corresponding mean
drug concentrations were 3.73 mg/L, 1.81 mg/kg, and
1.56 mg/kg. In the ten patients receiving the drug 14 h and
2 h (range 1.5–2.5 h) preoperatively, corresponding drug
concentrations were 6.26 mg/L, 2.97 mg/kg, and 2.54 mg/
kg (Malincarne et al 2006).
As with other quinolones, moxifloxacin penetrates well
into polymorphonuclear leukocytes (mean ± SD internal
concentration = 54 ± 0.5 mg/L with an external medium
concentration of 4.5 mg/L) (Mandell and Coleman 2001).
Moxifloxacin also penetrates well into macrophages (with
an external concentration of 4 mg/L, the mean internal–
external concentration ratio = 13.4 (in cells infected with S.
aureus) and 11.4 (in non-infected cells), p=0.02) (Seral et
al 2003).
Moxifloxacin elimination occurs via a combination of
hepatic metabolism, biliary secretion, renal excretion, and
perhaps, transintestinal secretion. It is metabolized to 2
inactive metabolites, M1 (N-sulfate) and M2
(acylglucuronide) (Stass et al 2004). Renal clearance (CLR)
of the parent compound involves glomerular filtration and
partial renal tubular reabsorption (Stass et al 1998; Stass
and Kubitza 1999). Fecal drug concentrations upon multiple
oral dosing are quite high, a result of nonabsorption, biliary
secretion, and, possibly, transintestinal secretion (mean ±
SD days 2, 4, and 7 values during 400 mg daily oral dosing
were 87.3 ± 2.4 mcg/g, 303.3 ± 1.8 mcg/g, and 573.3 ±
1.9 mcg/g, respectively) (Burkhardt et al 2002). Mass
balance studies using oral drug have demonstrated that
(mean ± SD) 44.8% ± 3.4%, 37.9% ± 3.6%, and 13.6% ±
2.8% of the dose is eliminated as moxifloxacin (19.4% ±
1.2% in urine and 25.4% ± 3.1% in feces), M1 metabolite
(2.5% ± 0.6% in urine and 35.5% ± 3.2% in feces) and M2
metabolite (13.6% ± 2.8% in urine and none in feces),
respectively (Stass and Kubitza 1999). Thus, the urinary
and fecal routes account for 35.4% ± 1.8% and 60.9% ±
5.1% of the dose, respectively (Stass and Kubitza 1999).
The M1 metabolite is a high clearance compound eliminated
mainly via hepatic metabolism and biliary secretion into
the feces. Renal secretion occurs via a net active tubular
secretion process (Stass and Kubitza 1999). The M2
metabolite is the main metabolite seen in plasma, undergoing
some presystemic clearance via glucuronidation and
excretion by the kidneys by active tubular secretion. Biliary/
fecal elimination is negligible (Stass and Kubitza 1999). A
summary of the pharmacokinetic parameters for
moxifloxacin in healthy volunteers is provided in Table 3
(Stass et al 1998, 2001, 2002, 2004; Ballow et al 1999; Stass
and Kubitza 1999; Sullivan et al 1999, 2001; Wise et al
1999; Lubasch et al 2000; Lettieri et al 2001; Burkhardt et
al 2002).
When pharmacokinetic parameters are weight-
normalized, there are no significant age- or gender-based
effects on moxifloxacin pharmacokinetics (Sullivan et al
2001; Pea et al 2006). Thirty-two individuals participated
in a single 400 mg oral dose study of the effects of renal
impairment on the pharmacokinetics of moxifloxacin and
its M1 and M2 metabolites. With moxifloxacin, there was
no significant relationship of AUC with creatinine clearance
(CrCl) (p=0.59). However, Cmax did fall as CrCl fell
(p=0.03). Significant correlations existed between
moxifloxcin Cmax (r=0.438, p=0.012), fractional renal
excretion (Fe) (r=0.613, p=0.0002) and CLR (r=0.6405,
p=0.0001) and CrCl. The M1 metabolite was little affected
by changes in renal function although significant
correlations existed between M1 metabolite Fe (r=0.620,
p=0.0002) and CLR (r=0.703, p<0.0001) and CrCl. For the
M2 metabolite, AUC rose as CrCl fell (p=0.0167) while
Cmax did not change (p=0.3042). Significant correlations
existed between M2 metabolite AUC (r=-0.565, p=0.0011),
CLR (r=0.736, p<0.0001) and Fe (r=0.514, p=0.0026) and
CrCl (Stass et al 2002).
Single and multiple dose pharmacokinetics of
moxifloxacin have also been evaluated in end-stage renal
disease patients undergoing hemodialysis (HD) and
continuous ambulatory peritoneal dialysis (CAPD).
Following a single oral 400 mg dose, the AUC’s of parent
compound in these patients were statistically similar to those
found generally in healthy volunteers. However, Cmax values
were reduced by about 45% (HD) and 33% (CAPD)
compared with historical healthy control subject data. The
systemic exposure to the M1 metabolite rose by 1.4- to 1.5-
fold (based on AUC) while that to the M2 metabolite rose
7.5-fold (based on AUC) and 2.5- to 3-fold (based on Cmax)
compared with historical healthy control subject data. The
possible consequences of increased metabolite exposure are
not known. Multiple once-daily oral dosing of 400 mg for 7
days in these patients produced systemic exposure (AUC)
similar to that seen in healthy volunteers. Steady-state Cmax
values in HD patients were approximately 22% lower than
those  in  healthy  volunteers  while  they  were  comparable
for CAPD patients. Dialysis removal of moxifloxacin was
low (9% by HD, 3% by CAPD) (Anonymous 2005).
Continuous renal replacement therapy (continuous
venovenous hemodiafiltration) does not affectTherapeutics and Clinical Risk Management 2006:2(4) 424
Guay
Table 3 Mean ± SD pharmacokinetic parameters of moxifloxacin in healthy adult volunteers
Reference n Regimen Cmax (mg/L) Tmax (h) t 1/2 (h) CL/F CLR Fe (%)
(L/h) (L/h)
(1) 11 400 mg PO x 1 2.53 ± 1.31 1.0a 14.6 ± 1.18 13.7 ± 1.16 3.17 ± 1.12 23.2 ± 2.7
(2) 12 400 mg PO qd
dose 1 3.10 ± 0.60
b 1.67 ± 0.96 10.6
a,b 11.6 ± 2.1 ––– –––
dose 7 3.98 ± 1.10
b 1.59 ± 0.79 14.9a,b 10.4 ± 2.0 ––– –––
(3) 12 400 mg PO x 1 2.50 ± 1.29 2 .0
a 15.6 ± 1.15 11.6 ± 1.21 2.58 ± 1.25 19.3 ± 2.8
(4) 8 400 mg PO x 1 4.38 ± 1.4 0.77
a 14.9 ± 1.5 9.2 ± 1.4 2.3 ± 1.3 24.2 ± 1.4
(5) 16 400 mg PO x 1 2.8 (31.7%)c 1.0a 11.5 (12.8%)c ––– ––– –––
(6) 8
d 200 mg PO x 1 1.31 1.28 13.16 10.61 2.25 19.63
8
e 1.55 0.97 12.42 10.38
b 1.84 16.60
8
f 1.92 1.50 11.47 8.05b 1.74 20.55
(7) 8 100  mg PO bid
x 5 days
day 1 0.63 ± 1.47 2.0
a 9.39 ± 1.08 13.1 ± 1.25 2.54 ± 1.28 15.8 ± 1.21
day 5 0.90 ± 1.28 1.5
a 13.7 ± 1.20 13.8 ± 1.22 3.32 ± 1.31 24.0 ± 1.24
8 200  mg PO bid
x 5 days
day 1 1.16 ± 1.96 1.5
a 10.4 ± 1.26 14.0 ± 1.33 3.24 ± 1.36 18.2 ± 1.24
day 5 1.96 ± 1.23 1.3a 15.0 ± 1.18 13.1 ± 1.26 3.08 ± 1.29 23.5 ± 1.34
7 400 mg PO qd
x 5 days
day 1 3.10 ± 1.34 0.5
a 9.6 ± 1.12 12.9 ± 1.12 2.33 ± 1.27 14.7 ± 1.25
day 5 3.24 ± 1.19 1.5
a 15.1 ± 1.05 11.8 ± 1.22 2.51 ± 1.14 21.3 ± 1.19
7 600 mg PO qd
x 10 days
day 1 4.21 ± 1.18 1.0
a 9.11 ± 1.16 11.9 ± 1.26 3.30 ± 1.62 23.0 ± 1.46
day 10 5.67 ± 1.19 1.5
a 13.7 ± 1.06 10.0 ± 1.23 2.41 ± 1.15 24.2 ± 1.18
(8) 12 400mg PO x 1 4.34 ± 1.61 1.02 ± 0.72 9.15 ± 1.62 ––– 30.5 ± 6.18g 19.9 ± 4.55
(9) 7 400 mg PO x 1 4.98 ± 1.01 1.0 ± 0.91 8.32 ± 1.70 147.8
h 22.3
h 15.10 ± 3.61
400 mg IV x 1 5.09 ± 1.11 ––– 8.17 ± 1.58 151.5
h 23.0
h 15.2 ± 3.40
(10) 10 100 mg PO x 1 1.15 0.86 13.5 ––– ––– 24.4
100 mg IV x 1 1.34 ––– 12.7 ––– ––– 25.3
(11) 7
i 400 mg PO qd
3
j x 10 days
day 1 3.36 (21.5%)c 1.49 (62.2%)c 9.30 (12.1%)c ––– ––– –––
day 10 4.52 (12.2%)c 1.24 (48.0%)c 11.95 (10.8%)c ––– ––– –––
400 mg PO x 1 2.53 ± 1.31 1.0
a 14.6 ± 1.18 13.7 ± 1.16 3.17 ± 1.12 23.2 ± 2.7
(12) 6 50 mg PO x 1 0.29 ± 1.25 1.75a 11.4 ± 1.11 12.9 ± 1.13 2.77 ± 1.22 20.4 ± 1.15
6 100 mg PO x 1 0.59 ± 1.21 2.0a 12.2 ± 1.11 11.8 ± 1.21 2.38 ± 1.25 18.9 ± 1.34
6 200 mg PO x 1 1.16 ± 1.35 2.50
a 14.0 ± 1.14 13.0 ± 1.20 2.64 ± 1.25 19.8 ± 1.16
7 400 mg PO x 1 2.50 ± 1.31 1.5a 13.1 ± 1.06 14.9 ± 1.18 3.03 ± 1.17 20.1 ± 1.20
7 600 mg PO x 1 3.19 ± 1.19 2.5a 12.5 ± 1.14 15.0 ± 1.11 2.67 ± 1.10 17.5 ± 1.16
7 800 mg PO x 1 4.73 ± 1.16 3.0
a 12.3 ± 1.13 13.4 ± 1.24 2.50 ± 1.28 18.7 ± 1.25
Abbreviations: bid, twice daily; Cmax, peak serum concentration; CL/F, total body clearance; CLR, renal clearance; Fe, fractional elimination in urine as unchanged
parent compound; IV, intravenous; Tmax, time to Cmax; t ½, terminal disposition half-life; PO, oral; qd, once daily.
Notes: 
aMedian; 
bLinks parameters that are significantly different (p ≤ 0.05); 
c% coefficient of variation; 
dYoung males (mean age, 32); 
eOlder males (mean age, 74);
fOlder females (mean age, 74); 
gmL/min/1.73m
2; 
hMean values in mL/min; 
iMale; 
jFemale.
References: 1, Stass et al 2004; 2, Burkhardt et al 2002; 3, Stass and Kubitza 1999; 4, Stass et al 2002; 5, Lettieri et al 2001; 6, Sullivan et al 2001; 7, Stass et al 2001; 8,
Lubasch et al 2000; 9, Wise et al 1999; 10, Ballow et al 1999; 11, Sullivan et al 1999; 12, Stass et al 1998.Therapeutics and Clinical Risk Management 2006:2(4) 425
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moxifloxacin disposition to a clinically-meaningful
extent (Fuhrmann et al 2004).
Clinical efficacy
This section will deal only with the clinical efficacy of
moxifloxacin in skin and skin structure infections (SSSIs).
Table 4 illustrates the results of moxifloxacin clinical trials
in uncomplicated and complicated SSSIs (Leal del Rosal,
Fabian, et al 1999; Leal del Rosal, Martinez, et al 1999;
Parish et al 2000; Anonymous 2005; Giordano et al 2005).
All have been active-controlled in design, with cephalexin
as the control in the three uncomplicated SSSI studies,
unspecified β-lactam/β-lactamase-inhibitor combinations in
the 2 unpublished complicated SSSI studies, and
piperacillin-tazobactam followed by amoxicillin-clavulanate
as the control in the one published complicated SSSI study.
As may be seen, there were no significant or substantial
inter-group differences in clinical or bacteriological efficacy
or tolerability.
These results should be interpreted while keeping in
mind potential study limitations. In general, these studies
did not provide evidence of power analyses conducted to
establish proper group sizes. Thus, they were underpowered
to avoid type II statistical errors (ie, false negative intergroup
differences), especially with respect to subgroup analyses
based on comorbidities or individual pathogens. Three of
five studies remain unpublished, available only as abstracts
or in the product information. The limitations of this should
be obvious to the reader. The extensive number and breadth
of exclusion criteria generated study populations much
different from the “real world” patients who would require
treatment. Hence, the generalizability of study results can
be questioned. Clinical trials of SSSIs have long been
difficult to design in a way that renders them rigorous and
reproducible. Although the publication of SSSI study design
criteria by the Infectious Diseases Society of America
(IDSA) have helped in this regard (Calandra et al 1992),
deficient study designs are, unfortunately, still far too
frequently seen. The ability of investigators to add anti-
anaerobic coverage (eg, metronidazole) for presumed mixed
SSSIs makes it impossible to judge whether or not the
anaerobic coverage of moxifloxacin is clinically-relevant.
Lastly, the definitions of clinical endpoints can vary between
SSSI studies, making it difficult to obtain a global
perspective of drug efficacy.
A recent case report detailed a case of a patient with an
infected cat-bite wound failing therapy with IV cefuroxime,
ciprofloxacin, and metronidazole which responded to the
addition of IV moxifloxacin (Draenert et al 2005). Another
case report documented successful therapy of a M.
thermoresistibile infection following knee replacement
surgery with long-term therapy using moxifloxacin and
doxycycline (Labombardi et al 2005).
A recent review of potential antitubercular drugs
included encouraging in vitro, in vivo, (animal) and pilot
human clinical data regarding moxifloxacin use in infections
due to M. tuberculosis (Duncan and Barry 2004). These data,
in conjunction with in vitro susceptibility data reviewed
earlier in this paper, suggest that moxifloxacin may play an
important role in the treatment of SSSIs caused by atypical
mycobacteria. Clinical trials in this area are warranted.
Safety
As with other quinolones, moxifloxacin is generally well-
tolerated, with the majority of adverse events referable to
the gastrointestinal tract (nausea, diarrhea, vomiting,
constipation, abdominal pain, vaginitis, taste alteration) or
the central nervous system (headache, dizziness)
(Anonymous 2005). There were only three adverse events,
judged by investigators to be at least possibly drug-related,
occurring in at least 2% of over 8600 moxifloxacin-treated
patients in the drug development process: nausea (6%),
diarrhea (5%), and dizziness (2%) (Anonymous 2005).
Premature study discontinuation rates for drug-related
adverse events were 2.9% (oral) and 4.6% (IV → oral)
(Anonymous 2005). Moxifloxacin is not associated with
the phototoxicity characteristic of lomefloxacin and
sparfloxacin (Man et al 1999) and has only been associated
with the “temafloxacin hypersensitivity syndrome” in 1
patient (Nori et al 2004). This patient exhibited toxic
epidermal necrolysis and fulminant hepatic failure leading
to death. Moxifloxacin is not associated with the hypo or
hyperglycemia seen with gatifloxacin therapy (Park-Wyllie
et al 2006).
In 2004, a cumulative safety review of oral and
intravenous moxifloxacin from the drug development
program and postmarketing surveillance studies was
published. For the oral agent, the database comprised 30
phase II/III active comparator studies (moxifloxacin
n=7368, comparators n=5687), one phase IV study
(n=18374), and 4 postmarketing observation studies
(n=27756). For the intravenous agent, the database
comprised two phase III active comparator studies
(moxifloxacin n=550, comparators n=579). With both
formulations, the commonest adverse events involved the
gastrointestinal tract (for the oral agent, nausea in 7.1% andTherapeutics and Clinical Risk Management 2006:2(4) 426
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Table 4 Clinical efficacy and tolerability of moxifloxacin in skin and skin structure infections (SSSIs)
Study # evaluable
Reference Design subjects (C/B)
a Regimens Results
Uncomplicated SSSIs
(1) MC/R/DB/PG 180/68 Moxi 400 mg PO Clinical cure/improvement rates at 7–21d after the
qd x 7 days end of therapy were 90% (Moxi) and 91%
(Ceph) (p=NS). Clinical response rates were lower
171/57 Ceph 500 mg PO in men than women, esp. with Moxi (86% men,
tid x 7 days 94% women; stats NA). Clinical response rates
were highest in ≥65 yo age group (95%, stats
NA). Clinical response rates with Ceph were
approx. equivalent for spontaneous infections
and those occurring with a wound while, for
Moxi, rates were higher for infections occurring
with a wound (96% vs. 87%, stats NA).
Bact. eradication/presumed eradication rates at
7–21 days after the end of therapy were 91% in
both groups (stats NA). For S. aureus,
eradication rates were 92% (Moxi) and 93%
(Ceph) (stats NA) while for Streptococcus
species they were 90% (Moxi) and 82% (Ceph)
(stats NA). AE profiles for the 2 drugs were
similar (stats NA). AEs occurred in 21% of Moxi
and 19% of Ceph patients. 9 AEs were serious/
life-threatening in 7 patients (1 with Moxi, 6 with
Ceph). AEs led to premature study D/C in 13
patients (6 Moxi, 7 Ceph). Majority of AEs were
referable to GI tract and skin and frequencies/
types were similar in the 2 groups.
.
(2) MC/R/DB/PG 191/100 Moxi 400 mg PO Clin. cure or improvement occurred in 93% of
qd x 5–14 days patients in both groups. Bact. eradication/
presumed eradication occurred in 89% (Moxi)
194/112 Ceph 500 mg PO and 94% (Ceph) of patients. Eradication rates
tid x 5–14 days
b for S. aureus were 92% (Moxi) and 89%
(Ceph), No mention was made of AEs and
results of statistical analyses NA.
(3) MC/R/DB/PG 21/18 Moxi 200 mg PO Clin. cure or improvement occurred in 95%
qd x 5–14 days (Moxi 200), 100% (Moxi 400), and 89% (Ceph)
of patients. Corresponding bact. eradication/
22/15 Moxi 400 mg PO presumed eradication rates were 72%, 80%, and
qd x 5–14 days 80%. Predominant pathogens were S. aureus
(37.5%), S. haemolyticus (18.8%), and E. faecalis
26/15 Ceph 500 mg PO (10.4%). All treatments were “well-tolterated”
tid x 5–14 days with “similar frequencies of drug-related AEs”.
Results of statistical analyses NA.
Complicated SSSIs
(4) MC/R/DB/PG 162/NA Moxi IV → PO Clin. cure or improvement occurred in 77.2%
(North America) (total of 7–14 days) of Moxi and 81.5% of β-lactam comparator
recipients (p=NS).
173/NA β-lactam/β-lactamase
inhibitor IV → PO
(total of 7–14 days)
Note: 
aClinically/bacteriologically; 
bCould add metronidazole 400 mg tid for anaerobic coverage; 
cMethicillin-suspectible strains.
Abbreviations: AE, adverse event; Amox-Clav, amoxicillin-clavulanate; Ceph, cephalexin; CHF, chronic heart failure; DB, double-blind; D/C, discontinuation; GI,
gastrointestinal; IV, intravenous; I + D, incision + drainage; MC, multicenter; Moxi, moxifloxacin; NA, not available; NS, non-significant; PG, parallel group; R, randomized;
qd, once daily; tid, thrice daily; Pip-Tazo, piperacillin-tazobactam; PMC, pseudomembrous colitis; PO, oral.
Reference key: 1, Parish et al 2000; 2, Leal del Rosal, Fabian, et al 1999; 3, Leal del Rosal, Martinez, et al 1999; 4, Anonymous 2005; 5, Giordano et al 2005.Therapeutics and Clinical Risk Management 2006:2(4) 427
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Table 4 Continued
Study # evaluable
Reference Design subjects (C/B)a Regimens Results
Complicated SSSIs
MC/R/PG 315/NA Moxi 400 mg Clin. cure or improvement occurred in 80.6%
(International) IV → PO of Moxi and 84.5% of β-lactam comparator
qd x 7–21 days recipients (p=NS).
317/NA β-lactam/β-lactamase
inhibitor IV → PO
(total of 7–21 days)
Pooled results (stats NA)
Surgical I + D or debridement occurred in 55%
of Moxi and 53% of β-lactam comparator
subjects. Success rates varied by diagnosis (61%
in infected skin ulcers to 90% in complicated
erysipelas). Clin. cure or improvement by
pathogen was as follows:
S. aureus
c: Moxi 82.2%, Comparator 87.6%
E. coli: Moxi 81.6%, Comparator 84.8%
K. pneumoniae: Moxi 91.7%, Comparator 70.0%
E. cloacae: Moxi 81.8%, Comparator 57.1%
(5) MC/R/DB/PG 180/119 Moxi 400mg IV → Clin. cure rates 10–42 days post-therapy were
PO (total of 79% (Moxi) and 82% (Pip-Tazo → Amox-Clav)
7–14 days) (p=NS). Clin. cure rates were similar by
187/119 Pip-Tazo 3.375 g IV infection type in the 2 groups except abscess
qd → Amox-Clav (79% Moxi vs. 93% Pip-Tazo → Amox-Clav,
PO 800 mg bid p=0.04). Univariate followed by multivariate
(total of 7–14 days) regression analysis identified the no. of surgeries
(ie, ≥2) as being an independent risk factor for
minimum duration failure of abscess cure. After adjusting for risk
of IV therapy was factors for failure of abscess cure, the difference
3 days. between groups disappeared (odds ratio, 1.05;
p=0.12). There were no significant differences
between the groups in bacteriologic eradication
rates by organism or for monomicrobial or
polymicrobial infections. AE rates were
comparable in the 2 groups (drug-related AEs
in 31% and 30% of Moxi and Pip-Tazo →
Amox-Clav patients, respectively; corresponding
rates of diarrhea were 5% and 8%, and nausea
were 4% and 2%; premature D/C for drug-related
AEs in 14 and 17 patients). Drug-related serious
AEs with Moxi included weakness, worsening of
drug reaction rash, cellulitis exacerbation, PMC,
and clinical failure and with Pip-Tazo →
Amox-Clav included cardiopulmonary arrest,
worsening CHF, allergic reaction, asthenia,
worsened skin eruption, allergic reaction,
persistent right leg abscess, bloody diarrhea,
osteomyelitis, and clinical failure.
Note: 
aClinically/bacteriologically; 
bCould add metronidazole 400 mg tid for anaerobic coverage; 
cMethicillin-suspectible strains.
Abbreviations: AE, adverse event; Amox-Clav, amoxicillin-clavulanate; Ceph, cephalexin; CHF, chronic heart failure; DB, double-blind; D/C, discontinuation; GI,
gastrointestinal; IV, intravenous; I + D, incision + drainage; MC, multicenter; Moxi, moxifloxacin; NA, not available; NS, non-significant; PG, parallel group; R, randomized;
qd, once daily; tid, thrice daily; Pip-Tazo, piperacillin-tazobactam; PMC, pseudomembrous colitis; PO, oral.
Reference key: 1, Parish et al 2000; 2, Leal del Rosal, Fabian, et al 1999; 3, Leal del Rosal, Martinez, et al 1999; 4, Anonymous 2005; 5, Giordano et al 2005.Therapeutics and Clinical Risk Management 2006:2(4) 428
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diarrhea in 5.2%; for the intravenous agent, nausea in 3.1%
and diarrhea in 6.2%). Premature discontinuation rates due
to adverse events to moxifloxacin were 2.7% (oral) and 6.0%
(intravenous) while mortality rates were 2.7% (oral) and
4% (intravenous). Cardiovascular adverse events, including
surrogate markers for arrhythmias such as tachycardia,
palpitations, syncope, and hypotension, occurred at rates
far below 1%. Blood sugar-related events were practically
nonexistent (Ball et al 2004).
In the same year, a similar retrospective review of the
phase II/III clinical trial database (32 trials, n=14731 patients
(moxifloxacin n=8474, active comparators n=6257)) and
postmarketing surveillance studies (n=46130) were
reviewed with a focus on adverse events involving glucose
metabolism. In the clinical trials, there were 0 and 3 drug-
related hypoglycemic adverse events with moxifloxacin and
active comparator patients, respectively (latter were 2 cases
with levofloxacin and 1 case with trovafloxacin). Drug-
related hypoglycemic events occurred in 7 moxifloxacin and
1 active comparator patients. No evidence was found
supporting the presence of drug–drug interactions with oral
antidiabetic drugs. In the postmarketing studies, no cases
of drug-related hypoglycemia were noted. This same paper
described results of in vivo (rat) studies utilizing single
30 mg/kg and 100 mg/kg oral doses of moxifloxacin,
gatifloxacin, and levofloxacin (positive control was
glibenclamide 10 mg/kg). Blood was sampled predosing and
at 0.5 h and 1.5 h postdosing. In fasted rates, glibenclamide
had the expected effect (blood glucose fell a mean of 24%
at 1.5 h postdose which was preceded by a rise in serum
insulin). Blood glucose was not significantly affected by
either moxifloxacin or levofloxacin but fell means of 8%
and 18% with 30 mg/kg and 100 mg/kg doses of gatifloxacin,
respectively. No significant effects on serum insulin were
noted with any quinolone. In fed rats, glibenclamide
increased serum insulin and reduced blood glucose
approximately 40% at 1.5 h postdosing. Again, moxifloxacin
and levofloxacin had no significant effect on blood glucose
or serum insulin. Gatifloxacin 30 mg/kg and 100 mg/kg
reduced blood glucose by means of 17% and 26%,
respectively. This was preceded by a reduction in serum
insulin (only significant at 0.5 h with 100 mg/kg dose). Thus,
the gatifloxacin effect was felt to be insulin-independent
(Gavin et al 2004).
Results of the last of the large retrospective database
reviews for safety purposes were published in 2005 and
focused on the safety of oral moxifloxacin in the clinical
trial database as a function of aging. The database involved
27 phase II/III clinical trials analyzed by age grouping (<65,
65–74, ≥75 years old) and treatment (moxifloxacin and
active comparators). Valid data were available from 12231
subjects (moxifloxacin n=6270, active comparators n=5961;
comparators were primarily clarithromycin and cefuroxime
axetil). The subject distribution by age was as follows:
n=9671 were <65, n=1631 were 65–74, and n=924 were
≥75 years old. The distribution of drug-related adverse
events comparing moxifloxacin with active comparators was
not affected by increasing age (p=0.43) nor were premature
discontinuations due to adverse events (p=0.552). The
number of deaths were also similar (moxifloxacin n=17,
active comparator n=19). No arrhythmias due to QTc interval
prolongation were noted in the entire population. The
differences in adverse event profiles across the 3 age groups
were not significant for moxifloxacin (p=0.599) with 1
exception. For drug-related adverse events with
moxifloxacin, the profiles did differ across the 3 age groups
(p=0.001) but, unexpectedly most rates increased as age fell
(eg, nausea, vomiting, dyspepsia, and vaginal moniliasis
rates rose as age fell but insomnia rates rose as age rose).
There were no clinically-significant differences between the
treatments in the prevalence of serious drug-related events
(≤1%) and these were not related to age. In 787 patients
who had pre and 3 day-post 12-lead electrocardiograms
(n=651 were <65, n=136 were ≥65 years old), the mean ±
SD QTC interval prolongation was 7 ± 25msec in the <65
group  and 2 ± 28 msec in the ≥65 group (p=0.055, trend)
(Andriole et al 2005).
Pharmacokinetic drug–drug
interactions
Based on the significant role of metabolism in the
elimination of moxifloxacin, a study was conducted to
evaluate the effect of concurrent use of a potent cytochrome
P450 isozyme 3A4 inhibitor (itraconazole) on moxifloxacin
pharmacokinetics. Nine days of itraconazole 200 mg orally
daily had no significant effect on the single-dose kinetics
of oral moxifloxacin 400 mg (administered on day 7 of the
9-day itraconazole regimen). Moxifloxacin also had no
significant effect on itraconazole kinetics (Stass et al 2004).
Moxifloxacin 400 mg orally daily had no significant effect
on theophylline total body clearance and terminal disposition
half-life in 2 studies (Guay 2005). Moxifloxacin 400 mg
orally once daily had no significant effect on the
pharmacokinetics or pharmacodynamics of warfarin in
healthy volunteers (Guay 2005). However, case reports have
documented moxifloxacin-associated increases in INRTherapeutics and Clinical Risk Management 2006:2(4) 429
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(international normalized ratio of prothrombin time) in
warfarin recipients (Elbe and Chang 2005; Guay 2005).
Pending additional information, patients receiving long-term
warfarin therapy in whom moxifloxacin is to be used should
be monitored for changes in INR. Moxifloxacin does not
significantly affect low-dose oral contraceptive or digoxin
pharmacokinetics (Guay 2005). Unlike the case with
ciprofloxacin, norfloxacin, levofloxacin, and gatifloxacin,
probenecid does not significantly alter the systemic
pharmacokinetics of moxifloxacin (Guay 2005).
Like all quinolones, moxifloxacin is susceptible to
interactions with multivalent cations, wherein the reductions
in bioavailability may be clinically-relevant and lead to a
loss of therapeutic benefit. For example, calcium carbonate
or calcium lactate-gluconate given immediately before and
12 h and 24 h after single-dose moxifloxacin resulted in a
mean 15% reduction in Cmax (p≤0.05) and a mean 2%
reduction in AUC (p=NS) (Guay 2005). Simultaneous
administration of single-dose ferrous sulfate lead to mean
reductions of 59 and 39% in single-dose moxifloxacin Cmax
and AUC, respectively (both, p≤0.05) (Guay 2005). Single-
dose magnesium-aluminum antacid administered
simultaneously with single-dose moxifloxacin resulted in
mean 61% and 59% reductions in Cmax and AUC,
respectively (both, p≤0.05). When the antacid administration
was delayed until 2 h after moxifloxacin administration, the
mean 7% reduction in Cmax was non-significant but the mean
26% reduction in AUC was significant (p≤0.05). Even
administering the antacid 4 h before moxifloxacin
administration still resulted in a significant reduction in
quinolone AUC (mean 23%, p≤0.05) although the mean 1%
fall in Cmax was not (Guay 2005). Sucralfate administered
simultaneously with and then 5 h, 10 h, 15 h, and 24 h
following single-dose moxifloxacin administration resulted
in mean 71% and 60% reductions in quinolone Cmax and
AUC, respectively (both, p≤0.05) (Guay 2005). Ranitidine,
a histamine-2 receptor antagonist, does not interact with
moxifloxacin (2 studies) and can be recommended as a




The only potentially clinically-relevant pharmacodynamic
drug–drug interaction with moxifloxacin involves additive
electrophysiological effects with other drugs that can also
prolong the QTc interval on the electrocardiogram (Table
5) (Guay 2005). Drugs which prolong cardiac repolarization
may, on rare occasions, be associated with the development
of polymorphous ventricular tachycardia (“torsades de
pointes”) which, in turn, may degenerate into ventricular
fibrillation. Quinolones cause a drug-specific, dose-
dependent prolongation of QTc interval by inhibiting
outward potassium currents in myocytes. In numerous in
vitro models examining the mechanism(s) underlying this
arrhythmogenic effect, sparfloxacin has been more potent
than moxifloxacin (= grepafloxacin) which, in turn, has been
more potent than the other tested quinolones (Guay 2005).
In in vivo (animal) models, sparfloxacin again was most
potent followed by the trio of moxifloxacin–gatifloxacin–
grepafloxacin (latter agent has been withdrawn from the
market) (Guay 2005). Concentration-response relationships
have been demonstrated in both in vitro and in vivo
preclinical models (Chen et al 2005).
In one healthy volunteer study, single 400 mg and 800 mg
oral doses of moxifloxacin caused mean ± SD 4.0% ± 5.1%
and 4.5% ± 3.8% QTc interval prolongation at rest compared
with baseline, respectively (both, p≤0.05). Significant QTc
interval prolongation occurred at all heart rates and across
the entire RR interval range (400–1000 msec). There were
no gender-dependent differences in results. The correlation
of moxifloxacin plasma concentrations and QT interval was
significant but weak (r=0.35) (Guay 2005).
Only two comparative studies of the effect of quinolones
on QTc intervals have been published. In the first, single
Table 5 Drugs prolonging the QTc interval that may potentially
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oral doses of levofloxacin (1000 mg), ciprofloxacin
(1500 mg) and moxifloxacin (800 mg) were evaluated in a
placebo-controlled, crossover trial in healthy volunteers.
Mean QT and QTc interval prolongation was significantly
greater for moxifloxacin compared with placebo for all end
points, but it was generally not for the other two quinolones.
The proportion of subjects with QTc interval prolongation
of 30 msec. or higher was greater with moxifloxacin (72%–
81%) compared with levofloxacin (33%–38%) and
ciprofloxacin (34%–40%) (Guay 2005). In the second, 13
healthy volunteers received three 7-day regimens in random
order: ciprofloxacin 500 mg twice daily, levofloxacin
500 mg once daily, and moxifloxacin 400 mg once daily.
Washout periods between treatments were one week in
length. Twelve-lead electrocardiograms were obtained
before, 2 h after the first dose, and at the end of each regimen.
At the end of 7 days, moxifloxacin prolonged QTc by a
mean of 6 msec compared with baseline (p=0.022) and a
mean of 11 msec from the 2 h baseline value (p=0.003).
Ciprofloxacin and levofloxacin had no significant effect on
QTc. No quinolone had a significant effect on QT dispersion,
a parameter felt to be a more selective marker for risk of
polymorphous ventricular tachycardia (Tsikouris et al 2006).
Further studies of QT dispersion, especially in patients
receiving quinolone therapy, with/without concurrent use
of other drugs which also prolong QTc, are warranted.
The lack of multiple dose studies and well-done
epidemiologic studies do not allow an assessment of the
clinical relevance of the above-cited findings. In a recent
randomized trial comparing the cardiac safety of IV/oral
moxifloxacin and levofloxacin in elderly patients
hospitalized for community-acquired pneumonia, the two
agents had similar cardiac rhythm safety profiles
(Morganroth et al 2005). However, it is prudent to use
caution when using moxifloxacin (and other quinolones) in
patients already receiving potentially arrhythmogenic drugs
(Table 5) (Guay 2005). Similarly, caution is warranted when
use is contemplated in patients with abnormal pretreatment
QTc intervals, electrolyte abnormalities (especially
hypokalemia, hypomagnesemia, rarely hypocalcemia),
starvation/liquid protein fast diets, and prior/current history
of coronary artery disease or arrhythmias.
Dosing
Moxifloxacin is available as 400 mg oral tablets and
premixed moxifloxacin 400 mg in 250 mL 0.8% sodium
chloride IV bags (Anonymous 2005). For SSSIs, the
recommended daily dose is 400 mg and the recommended
durations of therapy are 7 days (uncomplicated infections)
and 7–21 days (complicated infections). Oral doses of
moxifloxacin should be administered at least 4 h before or
8 h after magnesium/aluminum antacids, sucralfate, metal
cations (eg, iron), multivitamin + mineral supplements
(especially with zinc), and didenosine chewable/buffered
tablets or pediatric powder for solution (Anonymous 2005).
No dosage adjustment is needed with any level of renal
impairment or mild or moderate (Child-Pugh Class A or B)
hepatic impairment (Anonymous 2005). In severe (Child-
Pugh Class C) hepatic impairment, there are no data to guide
the clinician (Anonymous 2005).
Conclusions
Optimal therapy for SSSIs requires careful patient
evaluation, including obtaining a thorough medical and
social history, performing a meticulous examination of the
lesion(s), and examination of Gram-stained smears of lesion
exudates. Early empirical antimicrobial therapy is the next
step after obtaining culture specimens, with subsequent
tailoring of therapy based on culture and sensitivity results.
Local measures, including debridement, are important
adjuncts to antimicrobial therapy. Selection of empiric
therapy for SSSIs depends on a number of factors, including
type of infection (uncomplicated vs complicated), location
of acquisition (community versus hospital), and local
sensitivity patterns for the commonest dermatologic
pathogens.
Older quinolones have been demonstrated to be
efficacious in the treatment of uncomplicated and
complicated SSSIs over the past 20 years (Blondeau 2002;
Sable and Murakawa 2003). In addition, more limited data
support the efficacy of the newer quinolones in the treatment
of uncomplicated SSSIs (gatifloxacin, levofloxacin 500 mg/
d, and moxifloxacin) (Leal del Rosal, Fabian, et al 1999;
Leal de Rosal, Martinez, et al 1999; Parish et al 2000;
Raghavan and Linden 2004). To these data may be added
those documenting the efficacy of high-dose levofloxacin
(750 mg/d) and moxifloxacin in the treatment of complicated
SSSIs (Raghavan and Linden 2004; Anonymous 2005).
What have other reviews recently said regarding the role
of quinolones in the treatment of SSSIs? In a recent review
of the diagnosis and treatment of facial bite wounds,
moxifloxacin was felt to be a reasonable monotherapy for
infected human facial bite wounds, especially in patients
who are penicillin-allergic. The suggested duration of a
prophylactic regimen ranged from 3–5 days (10–14 days if
bone was involved). For treatment, if bones or joints wereTherapeutics and Clinical Risk Management 2006:2(4) 431
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involved, a duration of 21+ days was recommended
(Stefanopoulos and Tarantzopoulou 2005).
In a review of the role of quinolones in the treatment of
SSSIs, Blondeau felt that both older and newer quinolones
had roles to play. The older ciprofloxacin-type quinolones
were recommended only in SSSIs where Gram-negative
aerobic bacilli were known pathogens, adding clindamycin
or metronidazole in suspected mixed infections. The newer
quinolones (including moxifloxacin) were recommended in
SSSIs where non-pseudomonal Gram-negative aerobic
bacilli were known pathogens, where there was a mixed
infection with anaerobes within the quinolone’s spectrum
of activity, where non-methicillin-resistant S. aureus gram-
positive aerobes were involved, and where Gram-positive
and Gram-negative aerobic pathogens were coexisting
(Blondeau 2002).
The first organization-based guidelines for the diagnosis
and management of SSSIs were published by IDSA in
November 2005 (Stevens et al 2005). Quinolones are
mentioned in the context of several general and organism-
specific infections. Quinolones are one of many empirical
choices in human and animal bite wounds, especially in
patients with severe penicillin allergies. Ciprofloxacin,
gatifloxacin, and moxifloxacin with/without clindamycin
or metronidazole are those specifically mentioned. Again,
quinolones are one of many empirical choices in SSSIs in
the immunocompromised host. A quinolone (probably
ciprofloxacin) plus an extended-spectrum β-lactam is the
specific quinolone mentioned. Quinolones are one of several
choices for the empiric management of each of three defined
types of surgical wound infections. In community-acquired
mixed necrotizing fasciitis, one option is a combination of
ciprofloxacin plus a β-lactam-β-lactamase inhibitor. In
SSSIs due to community-acquired MRSA, the newer
quinolone group (including moxifloxacin) is one option
(author’s comment: based on 20 years of experience with
quinolones in infections due to MRSA, the likelihood of
the development of resistance to quinolones during such
use is quite high. caution is warranted). Lastly, in infected
wounds after intestinal or genital tract surgeries, a
combination of a quinolone plus one of clindamycin/
metronidazole/chloramphenicol/β-lactam-β-lactamase
inhibitor is one option. Quinolones are mentioned in the
context of the patient with severe penicllin allergies. In
cutaneous anthrax, ciprofloxacin is the drug-of-choice
(newer quinolones are also considered likely effective). In
erysipeloid, quinolones are options only in patients with
severe penicillin allergies. Lastly, among many options,
levofloxacin and ciprofloxacin are considered options for
tularemia but only in mild to moderate illness.
Evolving resistance trends, especially amongst
staphylococci and enterococci, and sporadic intolerance to
conventional β-lactam therapy have led to the need for novel
options with proven efficacy and tolerability. Moxifloxacin
is comparable in both efficacy and tolerability with
conventional agents for SSSIs and is also effective against
many organisms resistant to these agents (exception:
methicillin-resistant staphylococci). It also possesses activity
against atypical mycobacteria associated with SSSIs
(moxifloxacin may develop into a first-line therapy for these
types of SSSIs but much work remains to be done before
this can be recommended). Despite its proven activity
against dermatologic pathogens, one could argue that its
use be carefully considered and, in general, restricted to
serious, life-threatening infections caused by resistant
pathogens or those patients with serious intolerances to
conventional therapy. In this way, the development and
progression of resistance might be blunted and its “lifespan”
as an antimicrobial for dermatologic infections prolonged.
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